ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Asymchem's Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility
Company

Asymchem’s Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility

Asymchem Laboratories (Tianjin) Co., Ltd. (SHE: 002821; HKG: 6821) announced that its Chemistry Macromolecule Base, located in the West District of the Tianjin Economic‑Technological Development Area (TEDA), completed a US…

Pfizer's Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Qyuns Therapeutics' Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Qyuns Therapeutics’ Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Innovent Biologics' IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia
CompanyDrug

Innovent Biologics’ IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia

Merck's Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation
CompanyDrug

Merck’s Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation

Duality Biologics' DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial
CompanyDrug

Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial

Novatim Immune Therapeutics' Y-0301 Receives FDA Clearance for Clinical Trials
CompanyDrug

Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials

Jiangsu Hengrui's SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma
CompanyDrug

Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma

Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC
CompanyDrug

Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC

Sichuan Kelun-Biotech's SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment
CompanyDrug

Sichuan Kelun-Biotech’s SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment

CSPC Pharmaceutical's CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment
Company

CSPC Pharmaceutical’s CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment

Show More